177镥-前列腺特异性膜抗原疗法治疗转移性去势抵抗性前列腺癌的前景 - Suppr

Suppr

超能文献

Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer.

作者信息

Kwekkeboom Dik

机构信息

Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

出版信息

J Nucl Med. 2016 Jul;57(7):1002-3. doi: 10.2967/jnumed.115.171363. Epub 2016 Feb 18.

DOI:10.2967/jnumed.115.171363

PMID:26912426

Abstract

摘要

相似文献

Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer.177镥-前列腺特异性膜抗原疗法治疗转移性去势抵抗性前列腺癌的前景

J Nucl Med. 2016 Jul;57(7):1002-3. doi: 10.2967/jnumed.115.171363. Epub 2016 Feb 18.

Re: Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer.

Eur Urol. 2016 Dec;70(6):1080-1081. doi: 10.1016/j.eururo.2016.08.028. Epub 2016 Aug 21.

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.使用¹⁷⁷Lu标记的PSMA-617对转移性去势抵抗性前列腺癌进行PSMA靶向放射性核素治疗。

J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16.

Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.镥-PSMA-617 放射性配体疗法作为转移性去势抵抗性前列腺癌患者的一种新的治疗选择。

Clin Nucl Med. 2016 Jul;41(7):522-8. doi: 10.1097/RLU.0000000000001240.

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.177Lu-DKFZ-PSMA-617治疗转移性去势抵抗性前列腺癌患者后的治疗剂量测定

Nucl Med Commun. 2017 Jan;38(1):91-98. doi: 10.1097/MNM.0000000000000606.

[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].[177镥-PSMA-617治疗、剂量测定及转移性去势抵抗性前列腺癌患者的随访]

Nuklearmedizin. 2016 Jun 28;55(3):123-8.

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.225Ac-PSMA-617用于转移性去势抵抗性前列腺癌的PSMA靶向α放射治疗。

J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.

Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.去势抵抗性前列腺癌患者中（177）Lu-PSMA-617前列腺特异性膜抗原（PSMA）抑制剂对正常器官和组织的治疗前剂量测定

Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83. doi: 10.1007/s00259-015-3125-3. Epub 2015 Jul 31.

Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.镥-PSMA-617 联合外放射治疗去势抵抗性转移性前列腺癌脑转移患者。

Clin Nucl Med. 2017 Sep;42(9):704-706. doi: 10.1097/RLU.0000000000001763.

A perspective on the EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands.

Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2666-2667. doi: 10.1007/s00259-021-05400-5. Epub 2021 May 13.

引用本文的文献

Imaging and dosimetry for radium-223: the potential for personalized treatment.镭-223的成像与剂量测定：个性化治疗的潜力

Br J Radiol. 2017 Aug;90(1077):20160748. doi: 10.1259/bjr.20160748. Epub 2017 Jun 27.

Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.镥标记的基于氨基磷酸酯的前列腺特异性膜抗原（PSMA）抑制剂：白蛋白结合剂对荷前列腺肿瘤小鼠生物分布和治疗效果的影响

Theranostics. 2017 Apr 27;7(7):1928-1939. doi: 10.7150/thno.18719. eCollection 2017.

PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.前列腺癌中使用放射性标记胆碱的PET及PET/CT：对20年临床研究的批判性重新评估

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1751-1776. doi: 10.1007/s00259-017-3700-x. Epub 2017 Apr 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验